A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157

Noah M. Hahn(Johns Hopkins University), Daniel M. Geynisman(Fox Chase Cancer Center), Timothy A. Masterson(Indiana University School of Medicine), David Jones(European Bioinformatics Institute), Thomas A. Gardner(Indiana University), Carolyn G. Chapman(Johns Hopkins University), Torrey M. Gallagher(Dartmouth–Hitchcock Medical Center), Elizabeth R. Plimack(Fox Chase Cancer Center), Costantine Albany(Indiana University Health), Ashley E. Ross(St. Jude Children's Research Hospital), Scott A. Turner(Dartmouth–Hitchcock Medical Center), Jong‐Chul Park(Chungnam National University), Angela Reed(Indiana University Health), Francine B. de Abreu(Dartmouth–Hitchcock Medical Center), Kyle McElyea(Indiana University Health), George E. Sandusky(Indiana University – Purdue University Indianapolis), George J. Netto(University of Pennsylvania), Richard E. Greenberg, Trinity J. Bivalacqua(University of Pennsylvania), Ziyue Liu(Indiana University – Purdue University Indianapolis), Liang Cheng(Brown University), Michael O. Koch(Indiana University School of Medicine), Richard Bihrle(Indiana University Health), T. Breen(Hoosier Cancer Research Network (United States)), Richard S. Foster(Indiana University Health), Alex S. Baras(Sidney Kimmel Comprehensive Cancer Center), Gregory J. Tsongalis(Dartmouth–Hitchcock Medical Center), Rhoda L. Loman(Indiana University Health), Marietta L. Moore(Indiana University Health)

Clinical Cancer Research

December 8, 2016

Cited by 72

|Science Translational Medicine|2014|5.1k

|New England Journal of Medicine|2016|4.4k

|Nature|2007|3.1k

|New England Journal of Medicine|2005|3.1k

|New England Journal of Medicine|2015|2.8k

Related Papers